Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 2

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

NCT00602667 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given. The chemotherapy in this study includes the drug methotrexate. This drug was an important part of the two clinical trials which resulted in the best survival results for children less than 3 years of age with medulloblastoma. Most patients treated on this trial will also receive radiation which is carefully targeted to the area of the tumor. This type of radiation (focal conformal or proton beam radiotherapy) may result in fewer problems with thinking and learning than radiation to the whole brain and spinal cord. PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system tumors.

Interventions

  • DRUG Induction Chemotherapy
  • DRUG Low-Risk Therapy
  • DRUG High-Risk Therapy
  • DRUG Intermediate-Risk Therapy

Study Locations (6)

California

  • Lucile Packard Children's Hospital at Stanford University Medical Center — Palo Alto
  • Rady Children's Hospital — San Diego

Minnesota

  • Children's Hospitals and Clinics of Minnesota - St. Paul — Saint Paul

Tennessee

  • St. Jude Children's Research Hospital — Memphis

Texas

  • University of Texas Southwestern Medical Center at Dallas — Dallas

Queensland

  • Lady Cilento Children's Hospital, Brisbane — Brisbane

Trial Details

FieldValue
Enrollment Target 293 participants
Start Date 2007-12-17
Est. Completion 2026-04
Phase Phase 2

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00602667

The ClinicalTrials.gov registry entry for NCT00602667 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 441 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 4 interventions — of which Induction Chemotherapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00602667 reports 6 study locations spanning 5 distinct geographic areas — top geographies include California, Minnesota, Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00602667 about?

NCT00602667 is a clinical study titled "Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma". RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given. The chemotherapy in this study includes the drug methotrexate. This drug was an important par...

What is the current status of trial NCT00602667?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 293 participants. The study started on 2007-12-17. Estimated completion is 2026-04.

What conditions does trial NCT00602667 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00602667?

The interventions under investigation include: Induction Chemotherapy (DRUG), Low-Risk Therapy (DRUG), High-Risk Therapy (DRUG), Intermediate-Risk Therapy (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00602667?

This trial is sponsored by St. Jude Children's Research Hospital, which has 441 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00602667 being conducted?

This trial has 6 study locations across California, Minnesota, Tennessee, Texas, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial